IP Library Patent Application 17624595
Patent Application
App. No. 17/624,595

PROCESS FOR PREPARATION OF EDOXABAN

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/624,595
Abstract

The present invention relates to process for preparation of N1-(5-Chloropyridin-2-yl)-N2-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo [5,4-c]pyridin-2-ylcarboxamido)cyclohexyl]oxamide p-toluene sulfonate monohydrate [edoxaban tosylate monohydrate], the compound of formula I, comprising reacting compound of formula VI with compound of formula V to obtain the compound of formula IV and further converting it to edoxaban tosylate monohydrate in an industrially feasible process.

Claims (15)

1 . A process for the preparation of edoxaban tosylate monohydrate, a compound of formula I comprising:

the process comprising:

a) reacting a compound of formula V with a compound of formula VI in the presence of a first base and a first solvent to obtain a compound of formula IV, wherein the solvent is dimethyl sulfoxide;

b) reacting the compound of formula IV with a deprotecting agent to obtain a compound of formula II or a salt thereof;

c) reacting the compound of formula II or salt thereof with a compound of formula III in the presence of a second base to obtain a compound of formula I-A;

d) reacting the compound of formula I-A with para toluene sulfonic acid in a second solvent to obtain a compound of formula I; and

e) optionally, recrystallizing the compound of formula I with a third solvent.

2 . The process according to claim 1 , wherein the first base used in step a) is triethylamine.

3 . The process according to claim 1 , wherein the first base used in step a) is added in one lot.

4 . The process according to claim 1 , wherein the deprotecting agent used in step b) is selected from the group consisting of ethyl acetate hydrochloride in an ethyl acetate solvent, hydrochloric acid in a dioxane solvent and hydrochloric acid in an acetone solvent.

5 . The process according to claim 1 , wherein the compound of formula II obtained in step b) is a dihydrochloride salt, a compound of formula II-A.

6 . The process according to claim 1 , wherein the third base used in step c) is selected from the group consisting of triethyl amine, and diisopropyl ethyl amine.

7 . The process according to claim 1 , wherein the second solvent used in step d) is selected from the group consisting of acetone, dimethyl sulfoxide, isopropyl alcohol, methanol, water and mixtures thereof.

8 . The process according to claim 1 , wherein the third solvent used in step e) is selected from the group consisting of acetone, dimethyl sulfoxide, methanol, isopropyl alcohol, methanol, water and mixtures thereof.

9 . The process according to claim 8 , wherein edoxaban tosylate monohydrate is crystallized from a solvent mixture of acetone and water.

Assignments (2)
CHANGE OF NAME Recorded Jan 7, 2025
From: GLENMARK LIFE SCIENCES LIMITED
To: ALIVUS LIFE SCIENCES LIMITED
Reel/Frame 069775/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2022
From: CHAND, PREM; PATIL, PRAMOD VITTHAL; JADHAV, BALASAHAB; LAD, SACHIN MAHADEO; NAIK, SAMIR; BHIRUD, SHEKHAR BHASKAR; SHAFAKAT ALI, NASIR ALI
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 058934/0645 →